Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

NCT04727996 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer

Interventions

DRUG: Sitravatinib
DRUG: Tislelizumab

Sponsor

Seoul National University Hospital

Collaborators

[object Object]